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Abstract
Purpose To investigate the impact of the Ala1330Val
(rs3736228, exon 18) and Val667Met (rs4988321, exon 9)
polymorphisms of the low-density lipoprotein receptor-
related protein 5 (LRP5) gene on peak bone mass in young
men.
Methods The Odense Androgen Study (OAS) is a popu-
lation-based study comprising 783 Caucasian men aged 20-
30 years. Genotyping was performed using real-time
polymerase chain reaction (PCR) or ﬂuorescence polari-
zation. Bone mineral density (BMD) measurements were
performed using dual-energy X-ray absorptiometry.
Results The CC, CT, and TT genotypes in Ala1330Val
were found in 75.6%, 21.8%, and 2.6% of the participants,
respectively. Similarly, the GG, GA, and AA genotypes of
Val667Met were found in 89.7%, 9.8%, and 0.5%,
respectively. For the Ala1330Val polymorphism, no sig-
niﬁcant differences between the genotypes were found
regarding BMD in the overall study population. However,
when analysis was restricted to non-sedentary men
(n = 589), a signiﬁcant association between the number of
T-alleles and BMD in the spine and whole body were
found. Each copy of the T-allele changed the Z-score of the
spine by (median and 95% conﬁdence interval) -0.21
[95% CI: -0.40; -0.03] (p\0.02). Analysis suggested an
association between the AA genotype in the Val667Met
polymorphism and increased body height and decreased
BMD of the femoral neck; however, no signiﬁcant gene-
dose effect of the A-allele could be demonstrated in the
whole population. When the analysis was restricted to non-
sedentary subjects, however, each number of A-alleles was
associated with a change in Z-score of -0.26 [95% CI:
-0.51; -0.01] (p = 0.04). No further signiﬁcant results
emerged with haplotype analysis.
Conclusion The Ala1330Val and Val667Met polymor-
phisms in the LRP5 gene are signiﬁcantly associated with
peak bone mass in physically active men.
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Family and twin studies have demonstrated that genetic
factors account for 50–80% of the inter-individual varia-
tion in bone mineral density (BMD) in both women and
men [1–9]. Polymorphisms in a number of genes affect the
bone phenotype regarding BMD, bone size, or fracture risk
[10]. Only a small part of the overall variation in BMD,
however, has been explained by the polymorphisms iden-
tiﬁed so far.
The transmembrane proteins low-density lipoprotein
receptor-related protein 5 (LRP5) and LRP6 are essential in
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DOI 10.1007/s00223-007-9088-zWnt signaling. They are expressed in many tissues
including osteoblasts and have been implicated in the
adaptive response of bone to mechanical load [11]. Located
on chromosome 11q12–14, activating mutations in the
LRP5 gene are responsible for rare conditions with a ‘‘high
bone mass phenotype’’ [12, 13] as well as autosomal
dominant osteopetrosis type 1 [14], and transgenic mice
carrying the LRP5 G171V mutation have increased bone
mass and bone biomechanical properties [15]. Conversely,
inactivating mutations are responsible for the osteoporosis
pseudoglioma syndrome [16] and this syndrome is reca-
pitulated by LRP5 inactivation in mice [17].
In addition to these mutations, a number of polymor-
phisms have been described in the LRP5 gene
(http://www.ncbi.nlm.nih.gov/SNP). One of these, the
Ala1330Val (rs3736228, exon 18) polymorphism, has been
associated with attenuated bone gain in prepubertal boys
[18], decreased BMD in Japanese [19], American [20],
Australian [21], and Dutch [22] women as well as in
elderly Dutch men [22]. It has also been associated with an
increased risk of fragility fractures in postmenopausal
Australian women [21] and in elderly Dutch men [22]. No
association, however, was found between this polymor-
phism and bone loss in elderly men and women [22].
Similarly, the Val667Met (rs4988321, exon 9) polymor-
phism was associated with attenuated bone gain in
prepubertal boys but not in girls participating in a 1-year
longitudinal Swiss study [18]. In the same study, this
polymorphism was also associated with decreased lumbar
spine bone mineral content and projected bone area and
there was a trend toward lower BMD in the spine [18].
These associations were mainly driven by men [18] and in
haplotype analysis including Ala1330Val, most of the
effect was conferred by the Val667Met polymorphism.
Moreover, in a case-control study by Ferrari et al. [23]o n
idiopathic osteoporosis in males, both LRP5 polymor-
phisms signiﬁcantly increased the odds ratio for
osteoporosis. Additionally, Val667Met was associated with
low stature in adults of both sexes [18]. Thus, current
evidence suggests that polymorphisms in the LRP5 gene
may be involved in the control of peak bone mass and may
increase the risk of osteoporosis in males [16,18, 23].
In the present study, we investigated the association
between the Ala1330Val and Val667Met polymorphisms
and peak bone mass in men in a population-based study.
Subjects and Methods
The Odense Androgen Study (OAS) is a population-based,
prospective, observational study on the interrelationship
between endocrine status, body composition, muscle func-
tion, and bone metabolism in young men. Details on the
design and inclusion of participants are reported elsewhere
[24]. In brief, 3,000 men aged 20–30 years were randomly
selected from the civil registration database in Fuenen
County, Denmark, and invited by mail to participate in the
study. These subjects also received a questionnaire
regarding smoking, medication, chronic diseases, drug
abuse, etc. A total of 2,042 questionnaires were returned,
and from these 859 men expressed interest in participation
in the clinical part of the study. Nineteen withdrew before
an appointment for inclusion was made. Ten men did not
meet with the inclusion criteria (Caucasian and age between
20–29 years), and another 3 men gave their notice after the
inclusion had stopped. Aside from these latecomers none of
the responders were excluded. Of the remaining 827 eligi-
ble subjects, 43 did not attend for their appointment and did
not wish to reschedule, but informed consent was obtained
from 784 men, with dropout from 1 subject. Thus 783
Caucasian men gave written informed consent and were
included in the OAS. These participants had similar age,
body mass index (BMI), lifestyle, socio-economic status,
and educational level as the background population, as
evaluated by questionnaires and demographic data (manu-
script in preparation). The protocol stipulated that subjects
with massive substance or alcohol abuse, malignant disease
or severe chronic disease be excluded; however, none of the
responders fulﬁlled any of these criteria. The study was
approved by the local Ethics Committee of Fuenen and
Vejle Counties (ﬁle number 20010198), conducted
according to the Helsinki Declaration, and declared in
ClinicalTrials.gov: NCT00150163, registered September 6,
2005.
Genotyping
DNA was isolated from whole blood samples using QIA-
amp DNA Blood Midi kits (Qiagen, Valencia, CA, USA).
The Ala1330Val polymorphism was analyzed using
Taqman primers and probes that were designed using Pri-
mer Express software (Applied Biosystems):
Sense: 50-GACGGCGAGGCAGACTGT-30
Antisense: 50-GCAGGGCCAGGGTCTTG-30
C probe: 50-FAM-TCAAAGTCCGCCTCGT-NFQ-30
T probe: 50-VIC-CACAGTCCACCTCGTC-NFQ-30
The real-time analysis was performed using the ABI
PRISM 7700 Sequence Detection System. To validate the
method, approximately 10% of the samples were repeated
and in total 17 samples—at least 5 of each genotype—were
sequenced.
The Val667Met polymorphism was analyzed using
ﬂuorescence polarization as described previously [25],
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123using AcycloPrime-FP SNP Detection kits (Perkin Elmer
Life Sciences, Boston, MA, USA). PCR fragments con-
taining the polymorphisms were generated using standard
conditions with the following PCR primers:
Sense: 5-gccTTcTTggTcTTcAccAg-30
Antisense: 50-cTTTgAggcAggAAcAgAgg-30
Enzymatic clean-up and subsequent AcycloPrime-FP reac-
tion with SNP primer (sense 50-ccTcgAgAccAATAAcAA
cgAc-30) were performed according to the instructions of
the kit manufacturer. Fluorescence polarization was read in
a Wallac Victor multilabel plate reader (Perkin Elmer Life
Sciences, Boston, MA, USA). Blank samples and samples
with known genotype were included as negative and
positive controls, respectively. A total of 10% of all
samples were sequenced and genotyping conﬁrmed in all
cases.
Anthropometrics and Lifestyle
Body weight, body height, sitting height, and arm span
were measured. Data regarding exercise habits were col-
lected using a self-administered questionnaire. Non-
sedentary lifestyle was deﬁned as participation in any form
of regular exercise.
Dual-Energy X-ray Absorptiometry (DXA)
BMD of the lumbar spine, hip, and whole-body was
measured using a Hologic 4500 DXA-scanner (Waltham,
MA, USA). The coefﬁcient of variation (CV) for BMD is
1.5%, 1.5%, and 0.7% in the lumbar spine, total hip, and
whole body, respectively. Lean body mass (LBM) and fat
mass was obtained from the whole-body scans.
Biochemistry
Serum samples were drawn after an overnight fast between
08.00 and 10.00 hours and stored for later analyses at
-80C. Serum concentrations of osteocalcin were mea-
sured by a luminoimmunoassay (BRAHMS Diagnostica,
Berlin, Germany) with an intra-assay and inter-assay CV of
5% and 8%, respectively.
Serum levels of type 1 collagen C-terminal telopeptide
(1CTP) were measured using radioimmunoassay (RIA)
(Orion Diagnostica, Espoo, Finland) with an intra-assay
and inter-assay CV of 4% and 6%, respectively. Bone-
speciﬁc alkaline phosphatase (bone-AP) concentration in
serum was determined enzymatically after monoclonal
antibody capture (Metra Biosystems, Mountain View, CA,
USA). The intra-assay CV was 2% and the inter-assay CV
12% for this analysis. Serum levels of 25-OH-vitamin D
were measured using a competitive radioimmunoassay
(DiaSorin, Stillwater, MN, USA) with an intra-assay CV of
6% and an inter-assay CV of 15%. Serum IGF-I was
determined in acid–ethanol extracts as described previ-
ously [26]. Intra- and inter-assay variation averaged less
than 5% and less than 10%, respectively.
Statistics
Data are reported as the mean ± SD, median (range), or
median [95% CI], as appropriate. BMD values are shown
in absolute values. Regarding the allele dose-analyses,
BMD values were transformed to Z-scores using the SD
observed in our population. Hardy-Weinberg equilibrium
was checked using chi-square analysis. Linkage disequi-
librium (D’) between polymorphisms was evaluated by
using GOLD software [27]. Haplotype analysis was
undertaken using FAMHAP software for constructing
haplotypes [28]. Comparisons between groups were per-
formed using one-way ANOVA, unpaired t-test or similar
nonparametric tests. Associations between parameters were
analyzed using Pearson’s regression analysis and multiple
linear regression analysis. Dichotomies were tested using
the chi-square test. A p value of less than 0.05 was con-
sidered signiﬁcant. Statistical analyses were performed
using SPSS 11.5 and SPSS 12.0.
Results
Genotype Frequencies
For the Ala1330Val polymorphism, the CC genotype was
found in 589 (75.6%), the CT genotype in 170 (21.8%),
and the TT genotype in 20 (2.6%), respectively (Table 1)
allele frequencies of 0.87 and 0.13 for the C- and T-alleles,
respectively.
Similarly, the GG, GA, AA genotypes of the Val667Met
polymorphism were found in 699 (89.7%), 76 (9.8%), and
4 (0.5%), respectively. This corresponds to allele fre-
quencies of 0.95 and 0.05 for the G- and A-alleles,
respectively.
Both allele distributions were compatible with Hardy-
Weinberg equilibrium (v
2 = 3.2, p = 0.07 and v
2 = 1.48,
p = 0.22). The two polymorphisms were not in complete
linkage disequilibrium (D’ = 0.955, R
2 = 0.33).
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123Covariates
Data on covariates in relation to genotypes are shown in
Table 1. No signiﬁcant differences regarding covariates
(age, body height, body weight, BMI, sitting height (not
shown), total fat mass, lean body mass, alcohol consump-
tion, smoking, serum 25-OH-D3, or serum IGF-I) were
seen between the genotypes of the two polymorphisms.
Regarding the Val667Met genotypes, however, subjects
with the AA genotype had signiﬁcantly increased body
height (190.7 ± 6.6 vs. 181.7 ± 6.8 and 181.3 ± 5.6 cm,
p = 0.02) and arm span (193.5 ± 6.8 vs. 183.3 ± 8.0 and
182.6 ± 6.9 cm, p = 0.04).
BMD in Relation to Age
In the spine, no relationship between BMD and age could
be detected. Maximum BMD in the total hip was observed
around the age of 22 years. In subjects above this age BMD
was signiﬁcantly lower (ANOVA, p\0.05). In subjects
aged 30 years, BMD was 5.5% lower that the observed
maximum.
Genotypes in Relation to BMD
Regarding the Ala1330Val polymorphism, no signiﬁcant
differences between BMD in the spine, hip, or whole body
were found between subjects with the CC, CT, and TT
genotypes. When the CT and TT genotypes were pooled,
whole-body BMD was signiﬁcantly lower in the CT + TT
compared with the CC genotype (1.21 ± 0.10 vs.
1.22 ± 0.10, p = 0.05).
Regarding the Val 667Met polymorphism, a signiﬁcant
difference in hip BMD was observed, since subjects with
the AA genotype had lower BMD (0.84 ± 0.07 vs.
0.95 ± 0.14 and 0.96 ± 0.15, p = 0.03).
Table 1 also shows the distribution of genotypes in
relation to sedentary/non-sedentary lifestyle, but no sig-
niﬁcant difference in lifestyle was found between any of
the genotypes.
Table 2 shows the gene-dose effect on BMD expressed
as the change in Z-score of each copy of the T- or A-allele,
respectively. The analysis was performed both with and
without adjustment for BMI, smoking (0/1), any continu-
ous medication (0/1), and serum 25-OH-D3 in the overall
study population (multiple regression analysis). Regarding
Table 1 Covariates, BMD, and lifestyle (sedentary/non-sedentary) by LRP5 genotypes (Ala1330Val and Val667Met polymorphisms)
Polymorphisms
Ala1330Val Val667Met
CC CT TT p values
(ANOVA)
GG GA AA p values
(ANOVA)
n 589 170 20 – 699 76 4 –
Age (years) 25.5 ± 2.8 25.3 ± 2.8 25.9 ± 2.7 NS 25.5 ± 2.8 25.3 ± 2.6 27.0 ± 1.8 NS
Body height (cm) 181.7 ± 6.8 181.5 ± 6.1 182.8 ± 7.7 NS 181.7 ± 6.8 181.3 ± 5.6 190.7 ± 6.3 0.02
Arm span (cm) 183.4 ± 8.2 183.1 ± 7.0 185.4 ± 8.9 NS 183.3 ± 8.0 182.6 ± 6.9 193.5 ± 6.8 0.04
Body weight (kg) 81.9 ± 11.8 81.1 ± 12.4 85.9 ± 16.7 NS 81.7 ± 12.1 82.2 ± 12.9 90.4 ± 12.2 NS
Body mass index (kg/m
2) 24.8 ± 3.3 24.6 ± 3.7 25.6 ± 4.1 NS 24.8 ± 3.3 25.1 ± 4.3 24.8 ± 1.8 NS
Total fat mass (kg) 14.9 ± 6.2 14.9 ± 7.3 17.7 ± 8.5 NS 15.3 ± 6.2 15.1 ± 6.7 17.9 ± 7.9 NS
Lean body mass (kg) 64.0 ± 7.3 63.3 ± 6.8 65.3 ± 9.0 NS 64.7 ± 6.9 64.4 ± 6.0 70.4 ± 7.0 NS
Units alcohol/week (n) 11.4 ± 10.2 10.7 ± 8.6 12.3 ± 8.7 NS 11.0 ± 9.4 10.8 ± 8.1 6.5 ± 7.3 NS
Cigarettes/day (n) 0 [0–45] 0 [0–35] 0 [0–25] NS 0 [0–35] 0 [0–30] 0 [0–1] NS
Serum 25-OH-D3 (nmol/l) 65.1 ± 27.9 64.2 ± 26.9 67.9 ± 28.6 NS 65.2 ± 27.5 63.0 ± 29.1 60.0 ± 25.4 NS
Serum IGF-I (lg/l) 199.9 ± 52.8 202.4 ± 50.3 191.0 ± 36.1 NS 27.6 ± 7.5 25.5 ± 6.6 27.3 ± 7.8 NS
Serum osteocalcin (mmol/l) 3.0 ± 1.1 3.1 ± 1.3 3.0 ± 1.0 NS 3.1 ± 1.2 2.8 ± 1.0 2.3 ± 0.5 NS
Serum 1CTP (lg/l) 5.0 ± 1.4 4.9 ± 1,5 5.1 ± 1.3 NS 5.0 ± 1.4 4.9 ± 1.4 4.9 ± 0.9 NS
Bone-AP (U/l) 26. 6 ± 8.1 28.4 ± 10.0 26.7 ± 8.3 NS 26.7 ± 8.2 25.8 ± 7.0 33.4 ± 16.4 NS
BMDspine (g/cm
2) 1.08 ± 0.12 1.07 ± 0.17 1.05 ± 0.13 NS 1.08 ± 0.12 1.07 ± 0.22 1.07 ± 0.15 NS
BMDhip (g/cm
2) 0.95 ± 0.14 0.94 ± 0.14 0.94 ± 0.15 NS 0.95 ± 0.14 0.96 ± 0.15 0.84 ± 0.07 0.03
BMDWB (g/cm
2) 1.22 ± 0.10* 1.21 ± 0.09 1.21 ± 0.11 NS 1.22 ± 0.10 1.21 ± 0.11 1.20 ± 0.08 NS
Sedentary/non-sedentary (n) 150/440 37/133 4/16 NS 171/528 18/58 1/3 NS
No signiﬁcant differences were found between the groups (ANOVA). This was true also if the CT and TT genotypes were pooled (t-test).
Genotypes were in Hardy-Weinberg equilibrium (Ala1330Val: v
2 = 3.2, p = 0.07; Val667Met: v
2 = 1.48, p = 0.22)
*p = 0.05 comparing the CC genotype with CT + TT pooled; NS, not signiﬁcant
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123the Ala1330Val polymorphism, whole-body BMD tended
to decrease with each copy of the T-allele (p = 0.07) in the
overall study population (n = 779). No signiﬁcant associ-
ation between number of T-alleles and BMD at the other
skeletal sites was found. Regarding the Val667Met poly-
morphism, no signiﬁcant gene-dose effect could be
demonstrated in the overall population.
When analysis was restricted to non-sedentary men
(n = 589), however, a signiﬁcant correlation between the
number of T-alleles at the Ala1330Val polymorphism and
BMD in the spine was found in both the unadjusted (-0.21
[95% CI: -0.40; -0.03], p = 0.02) (Fig. 1) and adjusted
analysis (-0.20 [95% CI: -0.37; -0.02], p = 0.01)
(Table 2). Similarly, each copy of the A-allele in the
Val667Met polymorphism decreased the lumbar spine
BMD in unadjusted (-0.26 [95% CI: -0.51; -0.01],
p = 0.04) and adjusted (-0.23 [95% CI: -0.46; -0.002],
p = 0.048) analysis.
Genotypes in Relation to Bone Markers
No signiﬁcant differences were observed between geno-
types of the Ala1330Val or Val667Met polymorphisms
regarding bone markers (Table 1).
Haplotype Analysis
The effect of haplotypes of the Ala1330Val and Val667-
Met polymorphisms on BMD adjusted for BMI, lean body
mass, smoking, drugs, and vitamin D are shown in Table 3.
No signiﬁcant association between BMD and haplotypes
was found. This was also the case when sedentary and non-
sedentary men were analyzed separately (not shown).
Discussion
We found a signiﬁcant association between the Ala1330-
Val and the Val667Met polymorphisms in the LRP5 gene
and BMD in young men, especially when physical activity
Table 2 Multiple regression analysis determining the change in BMD Z-score for each copy of the T- or A-allele
Polymorphism
Ala1330Val Val667Met
Z-score Unadjusted Adjusted
a Unadjusted Adjusted
a
Total population (n = 779)
BMDspine -0.11 (-0.29; 0.06)
NS -0.10 (-0.27; 0.06)
NS -0.044 (-0.28; 0.19)
NS -0.054 (-0.27; 0.16)
NS
BMDhip -0.03 (-0.20; 0.11)
NS -0.02 (-0.17; 0.11)
NS 0.018 (-0.20; 0.23)
NS 0.002 (-0.22; 0.21)
NS
BMDWB -0.13 (-0.27; 0.11)
p = 0.07 -0.12 (-0.25; 0.01)
p = 0.07 -0.085 (-0.30; 0.13)
NS -0.11 (-0.33; 0.10)
NS
Non-sedentary (n = 589)
BMDspine -0.21 (-0.40; -0.03)
p = 0.02 -0.20 (-0.37; -0.02)
p = 0.01 -0.26 (-0.51; -0.01)
p = 0.04 -0.23 (-0.46; -0.002)
p = 0.048
BMDhip -0.08 (-0.26; 0.09)
NS -0.06 (-0.22; 0.10)
NS -0.08 (-0.33; 017)
NS -0.07 (-0.32; 0.19)
NS
BMDWB -0.17 (-0.33; -0.01)
p = 0.04 -0.15 (-0.30; 0.01)
p = 0.07 -0.17 (-0.41; 0.08)
NS -0.18 (-0.44; 0.07)
NS
Data are shown as mean effect and 95% conﬁdence interval. Z-scores were derived from the study population itself
a Adjusted for BMI (ln-transformed), lean body mass (ln-transformed), smoking (0/1), any continuous medication (0/1), and serum 25-OH-D3
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Fig. 1 BMD of the lumbar spine, total hip, and whole body in
relation to the genotype regarding the Ala1330Val (upper panel) and
the Val667Met (lower panel) polymorphisms in the LRP5 gene.
Participants with a non-sedentary (left) and sedentary lifestyle (right)
are displayed. Data are shown as the mean ± SE.
(*)p\0.10,
*p\0.05
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123was taken into account as confounder. This ﬁnding sup-
ports a number of recent papers reporting signiﬁcant
associations between polymorphisms in this gene and
BMD [18, 19, 21, 22]. Some of these studies involved or
were restricted to men [18, 22, 29, 30]. Moreover, Ferrari
et al. [18] suggested that the polymorphisms in the LRP5
gene are associated with bone gain in prepubertal boys.
Only one study [25] failed to demonstrate an association
between variations in the LRP5 gene and BMD, but most
likely this is due to their restricted sample size (n = 219).
Major disruption of the LRP5 gene (homozygous non-
sense or frame-shift mutations) resulting in loss-of-function
has been demonstrated to be responsible for the osteopo-
rosis pseudoglioma syndrome [16]. Conversely, a number
of dominantly inherited gain-of-function mutations result
in high bone mass phenotypes [12–14] and autosomal
dominant osteopetrosis type 1 [14]. Minor changes in this
gene, i.e., frequently occurring polymorphisms, may also
be of importance in the regulation of bone mass as sug-
gested by the association studies mentioned above. Further
support comes from mapping a quantitative trait locus for
BMD to chromosome 11q12–13 in some [31, 32] but not
all studies [7, 33, 34]. In a case-control study comprising
78 men with idiopathic osteoporosis and 86 controls, Fer-
rari et al. [23] found that Ala1330Val and Val667Met
conferred an odds ratio for osteoporosis of 2.98 (95% CI:
1.03–8.81) and 3.27 (95% CI: 1.43–7.44), respectively.
Also, a single prospective study [21] comprising 1,301
elderly Australian women demonstrated that the
c.3357A[G (rs556442) polymorphism was associated
with decreased BMD and increased incidence of fractures.
This polymorphism located in exon 15 is synonymous but
was found to be in linkage disequilibrium with Ala1330Val
[21]. Similarly, Mizuguchi et al. [19] found a linkage
equilibrium block comprising exons 7 to 18. In our study,
no signiﬁcant effect of Ala1330Val or Val667Met on BMD
was found apart from the ANOVA analysis which sug-
gested that the AA genotype at Val667Met was associated
with low BMD of the hip and increased body height. The
number of participants with this genotype, however, was
low (n = 4) and we found no signiﬁcant gene-dose effect to
back this ﬁnding. In non-sedentary subjects, however, we
found a signiﬁcant association between Ala1330Val
genotype and the Val667Met and Z-score BMD in the
spine both in unadjusted analysis and when adjusted for
BMI, smoking, continuous medication, and serum levels of
25-OH-D3. Further, we observed an association between
Ala1330Val and whole-body BMD in the unadjusted
analysis. This interaction between lifestyle (sedentary/non-
sedentary), LRP5 genotype, and BMD has not previously
been reported. Such an association is fully in line with the
proposed role of LRP5 as a player in adapting bone to
weight-bearing. LRP5 acts as a co-receptor for Wnt pro-
teins and is expressed in the osteoblast and a number of
other cell types. The Ala1330Val (exon 18) polymorphism
results in a substitution of alanine with the chemically
similar valine. No functional studies have been performed
on this polymorphism; however, the polymorphism is
located within the second LDL-repeat of LRP5 [22] and
this region is involved in the ligand binding of the LDL-
receptor [35]. Also, preliminary results have shown that
drugs that inhibit Dkk binding to LRP5 increase bone
formation in vitro [36] and LRP5 seems to be involved in
the adaptive response of bone to mechanical load and may
be partly responsible for the ‘‘mechanostat’’ [11]. It is
presently unclear why association between the Ala1330Val
and Val667Met genotypes and BMD was found only in the
spine and not in the hip in the non-sedentary group. Dif-
ferences between the skeletal sites regarding loading
pattern (compression vs. bending) and bone architecture
(trabecular vs. cortical) may be important.
In our study, the numbers of T-alleles and A-alleles of
the Ala1330Val and Val667Met polymorphisms, respec-
tively, were associated with a decrease in BMD of the
lumbar spine of 0.2 SD in the non-sedentary participants
(i.e., approximately 2.5%). Previous studies have assessed
this impact to be from 1% [20] to 15% [18] in women and
men and women, respectively. While a number of genes
have been associated with bone mass in women (e.g., PTH
[37], alpha-1 chain of type 1 collagen [10], vitamin D
Table 3 The effect of haplotypes of Ala1330Val and Val667Met polymorphisms on BMD adjusted for BMI, lean body mass, smoking, drugs,
and vitamin D
Haplotypes
Ala1330Val C T
Val667Met G A G A p
n 1331 3 129 81
BMDspine (g/cm
2) 0.008 ± 0.96 -0.42 ± 0.65 -0.09 ± 0.90 -0.04 ± 1.60 NS
BMDhip (g/cm
2) -0.002 ± 1.01 0.97 ± 1.48 -0.0005 ± 0.95 -0.04 ± 1.0 NS
BMDWB (g/cm
2) 0.02 ± 1.01 0.70 ± 0.59 -0.10 ± 0.87 -0.14 ± 1.04 NS
Data are shown as the mean ± SD. No signiﬁcant associations between BMD and haplotypes were found when sedentary and non-sedentary men
were analyzed separately (not shown)
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123receptor [38], transforming growth factor beta-1 [39],
interleukin-6 [40], and osteoprotegerin [41]), only a few
genes have been shown to be associated with peak bone
mass in men. We have previously reported that the
MTHFR gene is associated with peak bone mass in the
same series of men as reported here [42]. Each of these
polymorphisms including the LRP5 gene only accounts for
a fraction of the variability in BMD; however, the 2.5%
impact suggested by our study is not trivial.
We found no association between either projected bone
area at the spine or hip, or body weight and any of the
polymorphisms; however, our data demonstrated a signif-
icant impact of the AA genotype of the Val667Met
polymorphism and body height as previously reported by
Ferrari et al. [18] and Koay et al. [29]. In our study, the
number of subjects with the AA genotype was, however,
very low (n = 4). Thus, this ﬁnding clearly needs conﬁr-
mation in other study designs.
The allele frequencies found in our study corresponded
closely to those reported in Dutch, Australian, Japanese,
and Korean populations [19, 21, 22, 30].
Our study has some limitations. We only tested two
polymorphisms in the LRP5 gene. We cannot, therefore,
rule out the possibility that the associations found in our
study could be due to other polymorphisms in the LRP5
gene or even in neighboring genes in linkage with the
polymorphisms tested. Indeed, Bollerslev et al. [21] found
that several of the polymorphisms in the LRP5 gene were
in linkage disequilibrium with each other in Australian
women. In our study, haplotype analyses were negative.
This might be due to the limited number of participants.
Testing large arrays of polymorphisms or haplotypes in
relation to many outcome variables (i.e., bone mass at
several skeletal sites), however, carry an increased risk of
detecting spurious associations. Also, our study had a
limited size. Given the observed genotype frequency and
BMD values, our study had the power to detect differences
in BMDof the spine between CC and CT + TT of 0.037 g/
cm
2 (alpha = 0.05 and beta = 0.80). Similarly, our study
had the power to detect differences of 0.070 g/cm
2 between
GG and GA + AA in the overall analysis.
Our study also has several strengths. First, it was pop-
ulation-based. In contrast to most similar studies [18, 20]
that recruited participants by advertisements, we recruited
our participants by direct mailing on the basis of the
National Personal Registry that includes all Danish citi-
zens. This enabled us to account meticulously for the
recruitment of our participants. Thus, our sample was not
skewed with respect to key socio-economic parameters
[24]. Second, our population had a relatively homogeneous
genetic background both due to a small inﬂux to our
population and since participants with a ﬁrst- or second-
generation immigrant background were excluded on the
basis on data from our national registry. Third, we selected
young men aged 20–30 years since these were expected to
have reached their peak bone mass. This was conﬁrmed by
our data demonstrating an inﬁnitesimal decrease in BMD
by age. Moreover, very few were afﬂicted with chronic
diseases or had long-term exposure of environmental fac-
tors that may affect bone mass.
We conclude that the Ala1330Val (exon 18) and
Val667Met (exon 9) polymorphisms of the LRP5 gene are
signiﬁcantly associated with lumbar spine peak bone mass
in physically active men, potentially accounting for 2.5%
of BMD in the spine. This gene-environment interaction
provides support for LRP5 as a mediator of load-induced
bone formation and suggests that this gene is involved in
the pathogenesis of osteoporosis in men.
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